Supporting this idea, serum paraoxonase and arylesterase activities of PON1 were significantly differentiated between non-treated and osimertinib-treated LC patient sera (Figure 3I, right and Figure 3—figure supplement 2B). This evidence concerns the gene PON1 and laryngotracheoesophageal cleft.